Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

IMpassion 130 trial results: Immunotherapy for metastatic breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 22.10.18
Views: 750
Rating:

Prof Peter Schmid - St Bartholomew Hospital London, UK

Prof Peter Schmid speaks with ecancer at ESMO 2018 in Munich to discuss results from the IMpassion 130 trial of atezolizumab versus placebo in combinations with nab-paclitaxel to treat advanced and metastatic breast cancers.

The experimental combination of PD1 immunotherapy produced improvements in PFS and OS among PD-L1 positive patients, though no benefit was seen in PD-L1 negative patients.

Prof Schmid discusses the tolerability of the drug and the significance of immunotherapy entering breast cancer therapy options, and considers upcoming trials employing checkpoint immunotherapy.

For more on this data, watch his presentation of the trial results at a conference session here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

War on Cancer 2018


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation